Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)

Authors:

Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant ( K d ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH–F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections.
Funding Information
  • Instituto de Salud Carlos III (PI23/00851)
  • Xunta de Galicia (ED431C 2025/05)
  • Centro Singular de Investigación de Galicia (ED431G 2023/03)
  • Instituto de Salud Carlos III (CM23/00104)
  • Xunta de Galicia (IN606A 2023/023)
  • Instituto de Salud Carlos III (FI23/00074)
  • Xunta de Galicia (IN606A 2024/033)
  • Instituto de Salud Carlos III (CM23/00095)
  • Instituto de Salud Carlos III (IN606B 2022/009)
  • Instituto de Salud Carlos III (JR21/00026)
  • Italian Ministry of University and Research and the European Union (B63C22001400007)
  • Instituto de Salud Carlos III (PI22/01212)
  • Instituto de Salud Carlos III (PI21/00704)
  • Instituto de Salud Carlos III (PI20/01212)
  • Instituto de Salud Carlos III (CB21/13/00055)
  • Xunta de Galicia (IN607D 2021/12)
  • Xunta de Galicia (IN607D 2024/08)
  • Xunta de Galicia (IN607A 2024/09)
  • Agencia Estatal de Investigación (PID2022-136963OB-I00/AEI/10.13039/501100011033)

This publication has 51 references indexed in Scilit: